Amor, Corina http://orcid.org/0000-0002-7654-6216
Fernández-Maestre, Inés
Chowdhury, Saria
Ho, Yu-Jui
Nadella, Sandeep http://orcid.org/0000-0002-3290-4018
Graham, Courtenay http://orcid.org/0009-0003-8928-7975
Carrasco, Sebastian E.
Nnuji-John, Emmanuella
Feucht, Judith
Hinterleitner, Clemens
Barthet, Valentin J. A. http://orcid.org/0000-0002-5396-3594
Boyer, Jacob A.
Mezzadra, Riccardo
Wereski, Matthew G.
Tuveson, David A.
Levine, Ross L. http://orcid.org/0000-0002-7884-1905
Jones, Lee W.
Sadelain, Michel http://orcid.org/0000-0002-9031-8025
Lowe, Scott W.
Article History
Received: 31 January 2023
Accepted: 18 December 2023
First Online: 24 January 2024
Competing interests
: C.A., J.F., M.S. and S.W.L. are listed as the inventors of several patent applications (62/800,188; 63/174,277; 63/209,941; 63/209,940; 63/209,915; 63/209,924; 17/426,728; 3,128,368; 20748891.7; 2020216486) related to senolytic CAR T cells. M.S. holds other unrelated patents on CAR technologies. C.A. is also an inventor in the patent application 63/510,997. C.A., M.S. and S.W.L. are advisors for Fate Therapeutics. M.S. also receives research support from Fate Therapeutics, is an advisor and has equity in Senecea Therapeutics, and holds other unrelated patents on CAR technologies. S.W.L. is on the scientific advisory board and has equity in ORIC Pharmaceuticals, Blueprint Medicines, Mirimus, Senecea Therapeutics, Faeth Therapeutics and PMV Pharmaceuticals. D.A.T. is a scientific cofounder and scientific advisory board of Mestag Therapeutics and is a member of the Scientific Advisory Board and receives stock options from Leap Therapeutics, Dunad Therapeutics, Cygnal Therapeutics and Mestag Therapeutics outside the submitted work. D.A.T. has received unrelated research grant support from Fibrogen, Mestag and ONO Therapeutics. None of these activities are related to the current publication. R.L.L. is on the supervisory board of Qiagen and is a scientific advisor to Imago, Mission Bio, Zentalis, Ajax, Auron, Prelude, C4 Therapeutics and Isoplexis. R.L.L. receives research support from Ajax, Zentalis and Abbvie and has consulted for Incyte, Janssen and AstraZeneca and has received honoraria from AstraZeneca for invited lectures. L.W.J. owns stock in Pacyclex and Illuminosonics. The other authors declare no competing interests.